Drug news
Talactoferrin fails FORTIS-M trial for NSCLC
The FORTIS-M trial of talactoferrin from Aggenix AG, investigated the effect of talactoferrin plus best supportive care (BSC) compared with placebo and BSC in patients with Stage IIIb/IV Non Small Cell Lung Cancer, whose disease had progressed following two or more prior treatment regimens. Results showed that median overall survival in the talactoferrin arm was just 7.5 months compared to 7.7 months for placebo, which has brought to an end the development programme .
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins